|Bid||355.200 x 0|
|Ask||357.000 x 0|
|Day's range||350.200 - 374.600|
|52-week range||141.100 - 449.600|
|Beta (5Y monthly)||-0.75|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
While the coronavirus pandemic has plunged global economies into recession, plummeted stock markets, it has also captured a snapshot of the impact of the crisis on the wealthy.
Mexico has received the first doses of a COVID-19 vaccine candidate from Chinese pharmaceutical company CanSino Biologics Inc. for a late stage-trial on between 10,000 and 15,000 volunteers, foreign minister Marcelo Ebrard said on Tuesday. The country aims to vaccinate nearly all of its population against COVID-19 by the end of 2021 after reaching accords with pharmaceutical companies and the World Health Organization-backed COVAX plan. "On October 30, the first doses were received to carry out phase three of clinical trials of the candidate vaccine from Cansino Bio," Ebrard said at a news conference, adding that it would be one of the world's largest COVID-19 clinical trials.
Falling COVID-19 infection numbers in Pakistan will not affect a Phase 3 clinical trial for a potential vaccine being developed by China's CanSino Biologics, which is expected to begin this month, according to officials running the trial. Pakistan’s drug regulator last month gave the go-ahead for the country’s first Phase 3 clinical trial for CanSino's candidate, Ad5-nCoV, which will be led by the government-run National Institute of Health (NIH) along with pharmaceutical company AJM - the local representative of CanSino.